Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March

 Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In
                                    March

  PR Newswire

  DUBLIN, Feb. 27, 2013

DUBLIN, Feb. 27, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
announced today that the company will participate in two upcoming investor
conferences. A live webcast of each presentation may be accessed from the
Investors section of the Jazz Pharmaceuticals website at
www.jazzpharmaceuticals.com . The conferences, presentation times and speakers
include:

  *Cowen and Company 33rd Annual Healthcare Conference in Boston, MA on
    Wednesday, March 6, 2013 at 8:40 a.m. EST/1:40 p.m. GMT. Kathryn Falberg,
    executive vice president and chief financial officer, will provide a
    business update.
  *Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 12,
    2013 at 9:00 a.m. EST/2:00 p.m. GMT. Bruce Cozadd, chairman and chief
    executive officer, will provide a business update.

An archived version of each webcast will be available for at least one week
following each respective presentation on the Investors section of the
company's website at www.jazzpharmaceuticals.com .

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on
improving patients' lives by identifying, developing and commercializing
innovative products that address unmet medical needs. The company has a
diverse portfolio of products in the areas of narcolepsy, oncology, pain and
psychiatry. The company's U.S. marketed products in these areas include:
Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia
chrysanthemi ), Prialt® (ziconotide) intrathecal infusion, Luvox CR®
(fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of
the U.S., Jazz Pharmaceuticals also has a number of products marketed by its
EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com
.

Website: http://www.jazzpharmaceuticals.com
Contact: For Investors, Kathee Littrell, Vice President, Investor Relations,
Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., +1-650-496-2717,
For Media, Ami Knoefler, Executive Director, Corporate Communications, Jazz
Pharmaceuticals plc, Ireland, + 353 1 638 1032, U.S., +1-650-496-2947
 
Press spacebar to pause and continue. Press esc to stop.